health
Phase 1 Trial Tests EGFR-Targeted Toxin in Recurrent Glioma
A single-site phase 1 trial evaluated D2C7-ATC, an EGFR-targeted antibody-toxin conjugate, in recurrent malignant glioma. Among 72 patients with IDH-wild-type recurrent glioblastoma, median overall survival was 7.9 months.